Rethinking How We Measure Brain Health.

Objective, scalable measurement of neurological and mental health decline remains a major unmet need in clinical practice and clinical trials. Diagnosis and monitoring of conditions such as Alzheimer's disease, Parkinson's disease, and depression often rely on episodic clinical assessments, subjective questionnaires, or resource-intensive imaging.

Current approaches are frequently:

• Infrequent and clinic-based
• Dependent on specialist availability
• Influenced by patient self-report or examiner variability
• Limited to snapshot measurements rather than continuous monitoring

Traditional cognitive testing captures performance at a single time point, which may miss subtle, early-stage changes or gradual progression. Inter-rater variability and contextual factors can reduce sensitivity and reproducibility, particularly in multicentre trials.

At the same time, biological biomarkers (e.g., imaging, CSF, blood tests) provide important molecular insight but are invasive, costly, and offer limited behavioural context regarding how functional change manifests in daily life.

In high-stakes clinical research and healthcare delivery, improving the sensitivity, scalability, and objectivity of behavioural monitoring can materially strengthen early detection, patient stratification, and outcome measurement.

Cosignity addresses this gap by transforming natural speech and sleep behaviour into continuous, AI-driven digital biomarkers that enable earlier, more accessible, and reliable cognitive assessment.

Scalable Digital Biomarkers for Early Detection

Cosignity is an AI-powered digital biomarker platform that transforms natural speech and sleep patterns into objective, scalable indicators of brain health.

It combines:

• Remote speech and sleep data capture (mobile and edge devices)
• Automated signal processing and feature extraction
• Multilingual AI modelling and progression analytics
• Quantitative outputs for diagnosis, cognitive scoring, and longitudinal monitoring

Unlike traditional cognitive assessments that rely on episodic, clinic-based testing, Cosignity enables continuous, low-burden monitoring of behavioural change over time. It converts everyday human behaviours into structured, measurable health signals.

What It Enables

By translating speech and sleep patterns into clinically meaningful metrics, Cosignity delivers:

• Objective and quantifiable cognitive readouts
• Reduced subjectivity and inter-rater variability
• Early detection of subtle functional change
• Continuous longitudinal monitoring
• Scalable remote deployment
• Minimal patient burden

Rather than replacing established clinical assessments or biological biomarkers, Cosignity integrates alongside them, adding a continuous behavioural intelligence layer that strengthens diagnosis, patient stratification, and treatment monitoring.

The result: earlier detection, more sensitive outcome measurement, and scalable brain health intelligence for healthcare systems, researchers, and industry partners.

Target Segments

Customers

• Pharmaceutical companies conducting clinical trials in neurology and psychiatry
• Digital health and wellbeing app/device manufacturers
• Healthcare providers and NHS trusts
• Contract Research Organisations (clinical-stage)
• Health insurers and care providers

End Users

• Neurologists and psychiatrists
• Sleep Clinics
• Clinical trial investigators
• Cognitive and behavioural researchers
• Care coordinators and case managers
• Patients and caregivers (for remote monitoring use cases)